Development of oral RA treatments, heated by Korean companies’ patent suits
Development of the Pfizer Pharmaceuticals Korea’s oral rheumatoid arthritis(RA) treatment Xeljanz(generic name: tofacitinib) has been heated.
According to the Intellectual Property Tribunal, the total 12 pharmaceutical companies prepared to enter the market by filing patent lawsuits to avoid Xel...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
